CSIMarket
 
Pulse Biosciences Inc   (PLSE)
Other Ticker:  
 
 
Price: $17.0800 $1.48 9.487%
Day's High: $17.12 Week Perf: 5.37 %
Day's Low: $ 15.29 30 Day Perf: -9.68 %
Volume (M): 121 52 Wk High: $ 22.69
Volume (M$): $ 2,074 52 Wk Avg: $11.16
Open: $15.44 52 Wk Low: $3.78



 Market Capitalization (Millions $) 977
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) -33
 Capital Exp. (TTM) (Millions $) 0

Pulse Biosciences Inc
Pulse Biosciences Inc is a medical technology company that specializes in developing and commercializing innovative therapies using its proprietary Nano-Pulse Stimulation (NPS) technology. This technology is designed to deliver controlled and high-amplitude nanosecond electrical pulses to treat various medical conditions.

The company primarily focuses on dermatology and aesthetic applications, with its flagship product being the CellFX System. The CellFX System utilizes NPS technology to disrupt targeted cells while sparing surrounding healthy tissue, providing a non-thermal, non-thermal ablative treatment option for dermatologic conditions.

Pulse Biosciences Inc aims to revolutionize the field of medical dermatology by providing physicians and patients with a safe, precise, and effective alternative to traditional treatments. The company continues to invest in research and development to explore new therapeutic applications for its NPS technology beyond dermatology, such as in oncology and cardiology.

Overall, Pulse Biosciences Inc is at the forefront of innovating medical technologies, striving to improve patient outcomes and reshape the approach to treating various health conditions.


   Company Address: 601 Brickell Key Drive Miami 33131 FL
   Company Phone Number: 906-4600   Stock Exchange / Ticker: NASDAQ PLSE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Pulsating Towards Innovation Pulse Biosciences Milestones in Cardiac and Soft Tissue Ablation

Published Thu, Aug 8 2024 12:47 PM UTC

''In the rapidly evolving field of medical technology, few innovations have garnered as much excitement as Pulse Biosciences, Inc.?s (Nasdaq: PLSE) recent breakthroughs in Nanosecond Pulsed Field Ablation (nsPFA). The company has made significant strides with two notable announcements: the commencement of a first-in-human feasibility study for a novel Cardiac Surgery System ...

Stocks on the Move

Pulse Biosciences Outperforms Market with 0.55% Share Performance

Published Tue, Jul 23 2024 11:45 AM UTC

In recent news, Pulse Biosciences Inc (NASDAQ: PLSE) has emerged as a strong performer in the market, with its shares outperforming the industry average by 0.55%. This achievement comes amidst a challenging environment for small-cap stocks, wherein concerns over an economic slowdown and higher interest rates have burdened the market. This article aims to provide a comprehen...

Stocks on the Move

for the articlePulse Biosciences Granted FDA Breakthrough Designation, Shines Light on Revolutionary Cardiac Surgery System; Shares Skyrocket to a 2-Year High ...

Published Thu, Jul 11 2024 5:05 AM UTC

Pulse Biosciences, a leading bioelectric medicine company, has recently received a significant boost from the Food and Drug Administration (FDA) with a breakthrough device designation for its cardiac surgery system. This breakthrough designation aims to accelerate the approval process and facilitate the adaptation of the company's innovative approach to cardiac surgeries. As...

Business Update

Pulse Biosciences Receives FDA Breakthrough Designation for Cardiac Surgery System, Offering Promising AF Treatment...

Published Mon, Jul 8 2024 12:47 PM UTC

Pulse Biosciences' Breakthrough Cardiac Surgery System Brings New Hope for Treating Atrial FibrillationMedical technology company Pulse Biosciences, Inc. has recently received a significant accolade from the U.S. Food and Drug Administration (FDA). The company announced that its Cardiac Surgery System, utilizing the innovative Nanosecond Pulsed Field Ablation (nsPFA) technol...

Business Update

Pulse Biosciences Successfully Completes First U.S. Procedure With CellFX nsPFA System Following FDA Clearance

Published Thu, May 9 2024 12:47 PM UTC

California-based leading bioelectronics company, Pulse Biosciences, Inc. (PLSE), recently announced the successful completion of its first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System, a significant medical milestone that follows the system's clearance by the Food and Drug Administration (FDA). Pulse Biosciences is known for developing and harnessing t...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com